The Effects of Dupilumab on the development of T1 associated disease
This study investigates whether dupilumab, a Type 2 inflammation-blocking agent commonly used to treat allergic diseases, is associated with an increased risk of developing Type 1 diseases in children. Using the PEDSnet electronic health record network, researchers conducted a multicenter retrospective cohort study involving children aged 6-17 with asthma and/or atopic dermatitis, comparing those treated […]